Methods and compositions for treating viral diseases

US10869873B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10869873-B2
Application numberUS-201615150293-A
CountryUS
Kind codeB2
Filing dateMay 9, 2016
Priority dateDec 6, 2011
Publication dateDec 22, 2020
Grant dateDec 22, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides a method for treating viral infections and coinfections through the use of inhibitory agents that prevent a unique viral structural protein motifs from binding to host proteins from the clathrin adaptor proteins family and subsequently preventing viral replication.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of inhibiting assembly or budding of Dengue virus, comprising contacting a host cell that is infected with Dengue virus with sunitinib or a pharmaceutically acceptable salt of sunitinib, wherein the sunitinib inhibits adaptor-associated kinase 1 (AAK1), thereby inhibiting assembly or budding of the Dengue virus. 2. The method of claim 1 , wherein said sunitinib or pharmaceutically acceptable salt of sunitinib blocks binding of a viral structural protein to a host protein. 3. The method of claim 1 , wherein said sunitinib or pharmaceutically acceptable salt of sunitinib competes with a viral structural protein for binding to a host protein. 4. The method of claim 1 , wherein said sunitinib or pharmaceutically acceptable salt of sunitinib competes with a host protein for binding to a viral structural protein. 5. The method of claim 1 , further comprising contacting said host cell with erlotinib, midostaurin, or a pharmaceutically acceptable salt or combination thereof. 6. The method of claim 5 , wherein the host cell is contacted with erlotinib or a pharmaceutically acceptable salt of erlotinib. 7. The method of claim 5 , wherein the host cell is contacted with midostaurin or a pharmaceutically acceptable salt of midostaurin. 8. The method of claim 1 , wherein assembly or budding of said Flaviviridae is inhibited.

Assignees

Inventors

Classifications

  • involving cells · CPC title

  • A61K31/553Primary

    having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title

  • Indoles, e.g. pindolol · CPC title

  • Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt (malt products for use as foodstuffs A23L) · CPC title

  • ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10869873B2 cover?
The invention provides a method for treating viral infections and coinfections through the use of inhibitory agents that prevent a unique viral structural protein motifs from binding to host proteins from the clathrin adaptor proteins family and subsequently preventing viral replication.
Who is the assignee on this patent?
Univ Leland Stanford Junior
What technology area does this patent fall under?
Primary CPC classification A61K31/553. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).